Literature DB >> 15597044

alpha-Synuclein filaments bind the transcriptional regulator HMGB-1.

Evo K Lindersson1, Peter Højrup, Wei Ping Gai, Daniel Locker, Davy Martin, Poul Henning Jensen.   

Abstract

Abnormal accumulation of alpha-synuclein filaments in Lewy bodies is a neuropathological hallmark of Parkinson's disease and sequestration of cellular protein into these protein aggregates may contribute to the degenerative process. We identified the transcriptional co-factor high mobility group protein 1 (HMGB-1) as a ligand for alpha-synuclein filaments by a filament spin-down technique, mass spectrometric peptide mapping and immunoblotting. HMGB-1 binds preferentially to aggregated alpha-synuclein and is present in alpha-synuclein filament-containing Lewy bodies isolated from brain tissue affected with dementia with Lewy bodies or Parkinson's disease. Our results demonstrate that alpha-synuclein filaments hold the potential for disturbing the cellular gene expression as they can sequester a component involved in cellular transcription regulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15597044

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  21 in total

1.  HMGB1 is involved in autophagy inhibition caused by SNCA/α-synuclein overexpression: a process modulated by the natural autophagy inducer corynoxine B.

Authors:  Ju-Xian Song; Jia-Hong Lu; Liang-Feng Liu; Lei-Lei Chen; Siva Sundara Kumar Durairajan; Zhenyu Yue; Hong-Qi Zhang; Min Li
Journal:  Autophagy       Date:  2013-01-01       Impact factor: 16.016

2.  High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products.

Authors:  Andréy Mazarati; Mattia Maroso; Valentina Iori; Annamaria Vezzani; Mirjana Carli
Journal:  Exp Neurol       Date:  2011-08-22       Impact factor: 5.330

3.  The prion hypothesis of Parkinson's disease.

Authors:  Yaping Chu; Jeffrey H Kordower
Journal:  Curr Neurol Neurosci Rep       Date:  2015-05       Impact factor: 5.081

Review 4.  High-mobility group box 1, oxidative stress, and disease.

Authors:  Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
Journal:  Antioxid Redox Signal       Date:  2011-04-01       Impact factor: 8.401

Review 5.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

6.  High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson's disease.

Authors:  Aslıhan Baran; Mahmut Bulut; Mehmet Cemal Kaya; Özlem Demirpençe; Bünyamin Sevim; Eşref Akıl; Sefer Varol
Journal:  Neurol Sci       Date:  2018-10-23       Impact factor: 3.307

Review 7.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

8.  α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly.

Authors:  Takayuki Oikawa; Takashi Nonaka; Makoto Terada; Akira Tamaoka; Shin-Ichi Hisanaga; Masato Hasegawa
Journal:  J Biol Chem       Date:  2016-05-19       Impact factor: 5.157

Review 9.  HMGB1 in development and diseases of the central nervous system.

Authors:  Ping Fang; Melitta Schachner; Yan-Qin Shen
Journal:  Mol Neurobiol       Date:  2012-05-13       Impact factor: 5.590

10.  Non-cell autonomous modulation of tyrosine hydroxylase by HMGB1 released from astrocytes in an acute MPTP-induced Parkinsonian mouse model.

Authors:  Soo Jeong Kim; Min Jeong Ryu; Jeongsu Han; Yunseon Jang; Min Joung Lee; Xianshu Ju; Ilhwan Ryu; Yu Lim Lee; Eungseok Oh; Woosuk Chung; Jun Young Heo; Gi Ryang Kweon
Journal:  Lab Invest       Date:  2019-05-01       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.